Geode Capital Management LLC Has $23.46 Million Stock Position in Artivion, Inc. (NYSE:AORT)

Geode Capital Management LLC lessened its stake in shares of Artivion, Inc. (NYSE:AORT) by 0.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 880,984 shares of the company’s stock after selling 5,039 shares during the quarter. Geode Capital Management LLC owned about 2.10% of Artivion worth $23,457,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in AORT. FMR LLC increased its holdings in shares of Artivion by 28.0% during the third quarter. FMR LLC now owns 115,184 shares of the company’s stock valued at $3,066,000 after acquiring an additional 25,176 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Artivion by 58.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after purchasing an additional 125,668 shares during the period. Barclays PLC grew its position in Artivion by 346.3% in the 3rd quarter. Barclays PLC now owns 70,877 shares of the company’s stock valued at $1,888,000 after purchasing an additional 54,996 shares during the period. Centiva Capital LP bought a new stake in Artivion during the 3rd quarter valued at $565,000. Finally, BNP Paribas Financial Markets raised its holdings in Artivion by 543.0% during the third quarter. BNP Paribas Financial Markets now owns 28,574 shares of the company’s stock worth $761,000 after buying an additional 24,130 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, VP Andrew M. Green sold 7,618 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the sale, the vice president now owns 33,503 shares of the company’s stock, valued at approximately $1,005,090. The trade was a 18.53 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Amy Horton sold 12,430 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the completion of the sale, the chief accounting officer now directly owns 139,989 shares in the company, valued at approximately $3,664,912.02. This trade represents a 8.16 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,447 shares of company stock worth $925,424. 8.10% of the stock is currently owned by corporate insiders.

Artivion Stock Down 1.2 %

AORT opened at $29.00 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. Artivion, Inc. has a one year low of $16.48 and a one year high of $30.45. The firm has a market capitalization of $1.22 billion, a P/E ratio of -1,450.00 and a beta of 1.75. The company has a fifty day moving average price of $28.18 and a 200-day moving average price of $26.55.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on AORT shares. Stifel Nicolaus upped their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, September 13th. JMP Securities reissued a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $34.00 target price on shares of Artivion in a research report on Monday, December 9th. Finally, Oppenheimer increased their price target on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $31.80.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.